BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genalyte Inc. To Launch Early Access Program For Maverick(TM) Next-generation Multiplexing Platform At Upcoming Immunology Conferences


5/1/2012 11:27:54 AM

SAN DIEGO, May 1, 2012 /PRNewswire/ -- Genalyte, Inc., a life sciences company developing and commercializing innovative next-generation multiplexing technology, today announced that it will launch an Early Access program for its Maverick Detection System and multiplexed autoimmune assays at two major immunology meetings in May. Genalyte will host booths and present scientific data on the performance of the Maverick platform at Immunology 2012, the 99th Meeting of the American Association of Immunologists, and at the 8th International Congress on Autoimmunity.

Genalyte's Early Access program enables scientists to gain pre-launch access to multiplexed autoantibody assays and the Maverick platform, which uses a patented silicon chip containing arrays of photonic microring sensors that can simultaneously analyze multiple proteins from a single small sample.

"These meetings will allow us to introduce the unique capabilities of the Maverick platform and our Early Access program to prominent immunology researchers," said Genalyte CEO Cary Gunn. "Feedback from our Early Access customers should be very helpful as we prepare for full commercialization of the Maverick platform in the coming months."

Maverick Detection System assays do not require the washes, incubations, reagents or other processing steps typically needed for sample preparation. They are simple to use and rapid results are available in only 15 minutes, including just two minutes of hands-on time. The Maverick platform has a large dynamic range and excellent sensitivity, with good reproducibility and no cross talk.

At Immunology 2012, Dr. Gunn will host a workshop discussing Genalyte's Maverick Detection System on May 7, 2012 from 10:00-11:00am in Room 203. Information on the Maverick Detection System will be available at Genalyte's Booth 103.

At the 8th International Congress on Autoimmunity, Genalyte will present at Poster Session 1 on May 10, 2012 from 10:00am5:00pm, Poster 1731. Information on the Maverick Detection System will be available at Genalyte's Booth 17A.

Immunology 2012 will be held in Boston, MA, May 4-8, 2012. For more information, visit http://immunology2012.org.

The 8th International Congress on Autoimmunity will be held in Granada, Spain, May 9-13, 2012. For more information, visit http://www2.kenes.com/autoimmunity/pages/home.aspx.

For more information about Genalyte and the Maverick platform, visit www.genalyte.com.

About Genalyte

Founded in 2007, Genalyte, Inc. is commercializing the Maverick detection platform based on the company's revolutionary Microring Sensor Technology, a new approach to multiplexing that leverages advances in silicon photonics to reduce or eliminate sample preparation, provide scalable multiplexing for both proteins and nucleic acids from a single small sample, and achieve excellent sensitivity and up to eight logs of dynamic range.

Contacts:


Genalyte, Inc.

Media:

Martin Gleeson

BLL Partners, LLC

VP, Development & Applications

Barbara Lindheim

+1 858 750-4470

+1 212 584-2276

martin@genalyte.com

blindheim@bllbiopartners.com

SOURCE Genalyte, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES